Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:10/6/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 6 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of dirucotide (MBP8298) in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the sixth of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of dirucotide (MBP8298) in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of dirucotide (MBP8298) versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Industry leader ... Asia Pacific. In this newly-created position, Gibbs will lead iLab’s business operations in ... suite of tools. This entails not only introducing iLab to potential partners but ...
(Date:9/1/2015)... ... September 01, 2015 , ... GenoCAD, a leading provider of ... of its flagship DNA design platform, which has been enhanced to boost user ... genetic parts, which in turn can be recombined using specific sets of rules ...
(Date:8/31/2015)... GUELPH, ON , Aug. 31, 2015 /PRNewswire/ - BIOREM ... new orders totalling $5.7 million. The orders are for air emission ... "Of particular note is a large order for a ... our equipment will be replacing a competitor,s system that failed ... see in our engineered solutions," said Derek S. Webb ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has announced the ... Growth, Trends & Forecasts (2014-2020)" report to their ... is estimated at $0.17 billion by 2018 at a ... The near future will bring Biomedical sensors that are ... sensors can be set to trigger alerts when unpredictable ...
Breaking Biology Technology:iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2
... the UW-Madison survive as a public university when public ... , ,Thats the question being posed these days by ... as a catalyst for Wisconsins high-tech, high-growth economy will ... ,Wiley also believes the university will become less accessible ...
... Wave Technologies Inc. (Nasdaq: TWTI) today announced it delivered ... RIKEN in Japan for use in various large scale genotyping ... been supplying its Invader SNP assays to Dr. Yusuke Nakamura, ... RIKEN, director of the Genome Center at the ...
... health insurance executive Tom Hefty has seen blue-ribbon government ... Hefty sometimes displays a thick file of reports spanning ... a reminder that writing thoughtful research papers is only ... a good thing that Hefty, who retired last year ...
Cached Biology Technology:UW-Madison Chancellor Wiley Challenges State to Think About Universitys Future 2UW-Madison Chancellor Wiley Challenges State to Think About Universitys Future 3Governors Growth Council hopes to go light on paperwork and heavy on ideas 2Governors Growth Council hopes to go light on paperwork and heavy on ideas 3
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/17/2015)... Conn. , Aug. 17, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... its new sales campaign for Q4 2015. The new ... marketing team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ... Marketing Group is a leader in retail driven marketing ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... 2+ Oscillations and Neurite Growth ,Kazunori ... This week, Kanemaru et al. explore the signaling pathway ... and the promotion of neurite growth. Their results reveal ... authors blocked Ca 2+ oscillations by preventing IP ...
... invasive tumors with tendrils that extend far from ... and leading to an invariably poor prognosis. In ... the open-access journal PLoS Biology, Angela Johnston, Donna ... injected immunocompromised mice with human gliomas and compared ...
... N.Y. Researchers at Rensselaer Polytechnic Institute have developed ... mistaken for a simple sheet of black paper. ... and geared toward meeting the trickiest design and energy ... vehicles. Along with its ability to function in ...
Cached Biology News:News tips from the Journal of Neuroscience 2News tips from the Journal of Neuroscience 3Beyond batteries: Storing power in a sheet of paper 2Beyond batteries: Storing power in a sheet of paper 3
... FLICA Apoptosis Detection Kit contains a green ... (FAM) derivative of valylalanylaspartic acid (VAD) fluoromethyl ... activity. When added to a population ... each cell and covalently binds to a ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... The VersArray ChipWriter Pro system, 220-240 ... array DNA, proteins, oligonucleotides, carbohydrates, lipids, and ... for microarray applications. This system can generate ... per glass slide or greater than 57,000 ...
... ChipWriter Pro systems are high-precision microarrayers ... other biological samples. VersArray ChipWriter Pro ... spot density, and reproducibility to deliver ... of substrates. Their modular component design ...
Biology Products: